디지털 맘모그래피 시장 - 세계 예측(2026-2032년)

The Digital Mammography Market is projected to grow by USD 3.30 billion at a CAGR of 10.12% by 2032.

Digital mammography has become a core modality in breast cancer screening and diagnostic imaging, replacing film-screen workflows with digital image capture, advanced visualization, and integrated reporting capabilities. The technology supports full-field digital mammography and digital breast tomosynthesis, enabling radiologists to evaluate breast tissue with image manipulation, faster access to prior studies, and streamlined storage through picture archiving and communication systems. Its relevance is reinforced by the global clinical burden of breast cancer, which the World Health Organization identifies as one of the most commonly diagnosed cancers among women worldwide. As healthcare systems prioritize earlier detection, digital mammography is increasingly aligned with screening programs, multidisciplinary breast care pathways, and quality assurance frameworks designed to improve diagnostic confidence and patient outcomes.

Transformative Shifts in the Digital Mammography Landscape

The digital mammography landscape is being reshaped by the transition from analog image acquisition to fully digital, interoperable, and data-driven breast imaging ecosystems. Healthcare providers are adopting digital breast tomosynthesis to reduce the limitations of tissue overlap in dense breasts, while contrast-enhanced mammography is gaining clinical attention as a complementary technique for selected diagnostic use cases. Workflow transformation is also accelerating through cloud-enabled image access, structured reporting, dose monitoring, and integration with electronic health records. At the same time, public health strategies are emphasizing organized screening, risk-based imaging, and improved access for underserved populations. Regulatory focus on image quality, radiation safety, and accreditation continues to influence procurement decisions, while radiology workforce pressures are increasing demand for tools that improve reading efficiency without compromising clinical rigor.

Cumulative Impact of Artificial Intelligence on Digital Mammography

Artificial intelligence is having a cumulative impact across the digital mammography value chain, from image acquisition quality checks to triage, lesion detection, breast density assessment, and decision support. Peer-reviewed clinical research has shown that AI-assisted mammography can help identify suspicious findings and support radiologist workflow, although implementation depends on validation, local population performance, regulatory clearance, and transparent clinical governance. AI is also being used to prioritize high-risk exams, reduce administrative burden, and support consistency in reporting. Its long-term value depends on high-quality training data, bias monitoring, integration with radiology information systems, cybersecurity safeguards, and human oversight. For industry stakeholders, AI is not replacing clinical expertise; it is becoming an enabling layer that can improve workflow resilience, support quality control, and expand the operational capacity of breast imaging services when deployed responsibly.

Key Regional Insights for Digital Mammography Adoption

In Asia-Pacific, demand for digital mammography is shaped by large population bases, expanding cancer screening initiatives, rising urban healthcare investment, and the need to improve early breast cancer detection across diverse health systems. North America remains characterized by mature screening infrastructure, broad use of digital breast tomosynthesis, established accreditation standards, and strong integration of breast imaging with electronic health records and specialist cancer care. Latin America is advancing through modernization of diagnostic imaging capacity, public awareness campaigns, and growing emphasis on access beyond major urban centers, although infrastructure gaps remain a critical consideration. Europe benefits from organized screening programs, radiological quality assurance protocols, and evidence-based adoption of breast imaging technologies, with variation across national healthcare systems. In the Middle East, investments in hospital modernization, women's health programs, and tertiary diagnostic services are supporting uptake of advanced mammography systems. Across Africa, digital mammography adoption is closely linked to cancer control planning, donor-supported health initiatives, workforce training, and the expansion of diagnostic capacity in regional referral centers.

Key Group Insights Across Major Economic and Health Alliances

Within ASEAN, digital mammography adoption is influenced by rising healthcare infrastructure development, national cancer awareness programs, and the need to expand screening access across urban and semi-urban populations. GCC countries are strengthening breast imaging capabilities through investment in advanced diagnostic centers, preventive health strategies, and specialized women's health services. The European Union supports structured breast cancer screening through harmonized quality principles, clinical guidelines, and cross-border emphasis on early detection and patient safety. BRICS countries present a diverse picture, combining large patient populations, increasing diagnostic imaging investment, domestic healthcare modernization, and persistent access disparities between urban and rural settings. G7 economies generally demonstrate strong institutional capacity for digital mammography, including established screening participation frameworks, technology assessment mechanisms, and integration with oncology care pathways. NATO member countries overlap significantly with high-income and upper-middle-income health systems where digital imaging infrastructure, radiology workforce planning, and cybersecurity standards are increasingly relevant to breast imaging modernization.

Key Country Insights Shaping Digital Mammography Utilization

The United States is defined by extensive mammography screening infrastructure, regulatory quality oversight, and growing adoption of digital breast tomosynthesis in both screening and diagnostic settings, while Canada emphasizes organized provincial screening programs and equitable access across geographically dispersed populations. Mexico and Brazil are advancing breast cancer detection through public health initiatives and imaging capacity expansion, with continued focus on reducing late-stage diagnosis and improving access outside large metropolitan areas. In the United Kingdom, Germany, France, Italy, and Spain, digital mammography is supported by national or regional screening programs, clinical quality standards, and structured referral pathways, while Russia continues to rely on modernization of diagnostic imaging networks and oncology service capacity. China and India represent high-priority environments due to large populations, increasing cancer awareness, hospital infrastructure expansion, and the need for scalable screening and diagnostic workflows. Japan and South Korea have advanced imaging ecosystems with strong technology adoption and preventive health engagement, while Australia combines organized screening services, regional access strategies, and high clinical emphasis on early breast cancer detection.

Actionable Recommendations for Digital Mammography Industry Leaders

Industry leaders should prioritize clinically validated digital mammography solutions that improve image quality, workflow efficiency, interoperability, and patient experience. Investment decisions should account for radiologist usability, integration with existing PACS and reporting systems, cybersecurity readiness, dose optimization, and service support across distributed sites. Organizations deploying artificial intelligence should establish governance models that include performance monitoring, bias assessment, audit trails, and clear human-in-the-loop protocols. For healthcare providers, strengthening screening participation requires patient education, culturally appropriate outreach, mobile imaging strategies where suitable, and coordination with primary care and oncology networks. Manufacturers and technology partners should support training, quality assurance, regulatory documentation, and lifecycle service models to ensure sustainable adoption. Public and private stakeholders should also align digital mammography programs with broader cancer control strategies, especially in regions where workforce constraints and infrastructure gaps limit access to timely breast imaging.

Research Methodology for Evidence-Based Digital Mammography Insights

This executive summary is developed through secondary research using verified public health, clinical, regulatory, and scientific sources relevant to digital mammography, breast cancer screening, diagnostic imaging, and artificial intelligence in radiology. The research approach emphasizes triangulation across international health agencies, peer-reviewed medical literature, national screening guidance, radiology quality standards, regulatory documentation, and healthcare infrastructure indicators. Insights are evaluated for recency, clinical relevance, geographic applicability, and consistency across credible sources. The analysis excludes market estimation, market sizing, market share assessment, and forecasting, focusing instead on technology adoption drivers, regional healthcare context, policy direction, operational considerations, and evidence-backed trends shaping digital mammography utilization.

Conclusion: Digital Mammography as a Cornerstone of Breast Health

Digital mammography is evolving from a standalone imaging modality into a connected, quality-driven component of comprehensive breast health management. The convergence of digital breast tomosynthesis, interoperable imaging platforms, structured reporting, and artificial intelligence is improving the way healthcare systems approach early detection, diagnostic confidence, and workflow efficiency. Regional adoption remains influenced by screening policy, healthcare infrastructure, workforce availability, reimbursement structures, and patient access. Organizations that combine clinical evidence, responsible AI governance, robust training, and patient-centered service delivery will be better positioned to strengthen breast imaging outcomes. As breast cancer remains a major global health priority, digital mammography will continue to play a central role in advancing early diagnosis and supporting more effective care pathways.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Digital Mammography Market, by Product Type

• 7.1. Introduction
• 7.2. Mammography Systems
  • 7.2.1. Full Field Digital Mammography Systems
    • 7.2.1.1. 2D Systems
    • 7.2.1.2. 3D Tomosynthesis Systems
  • 7.2.2. Analog To Digital Conversion Kits
    • 7.2.2.1. Computed Radiography Upgrade Kits
    • 7.2.2.2. Direct Radiography Retrofit Kits
• 7.3. Mammography Workstations

8. Digital Mammography Market, by Procedure Type

• 8.1. Introduction
• 8.2. Screening Mammography
• 8.3. Diagnostic Mammography
• 8.4. Interventional Mammography

9. Digital Mammography Market, by Modality

• 9.1. Introduction
• 9.2. Standalone Systems
• 9.3. Mobile Mammography Systems

10. Digital Mammography Market, by Patient Type

• 10.1. Introduction
• 10.2. Adult
• 10.3. Geriatric

11. Digital Mammography Market, by Application

• 11.1. Introduction
• 11.2. Breast Cancer Screening
• 11.3. Diagnostic Imaging
• 11.4. Follow-up Imaging
• 11.5. Research & Development

12. Digital Mammography Market, by End-User

• 12.1. Introduction
• 12.2. Ambulatory Surgical Centers
• 12.3. Hospitals
  • 12.3.1. Public
  • 12.3.2. Private
• 12.4. Specialty Clinics

13. Digital Mammography Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Digital Mammography Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Digital Mammography Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Agfa-Gevaert NV
• 17.2. Allengers Medical Systems Ltd
• 17.3. Beijing Wandong Medical Technology Co Ltd
• 17.4. BMI Biomedical International Srl
• 17.5. Canon Inc
• 17.6. Carestream Health
• 17.7. DMS Imaging
• 17.8. Fujifilm Corporation
• 17.9. GE HealthCare
• 17.10. General Medical Merate SpA
• 17.11. Genoray Co Ltd
• 17.12. Hologic Inc
• 17.13. Idetec Medical Imaging
• 17.14. IMS Srl
• 17.15. Italray Srl
• 17.16. Konica Minolta Inc
• 17.17. Koninklijke Philips NV
• 17.18. Medi-Future Inc
• 17.19. Metaltronica SpA
• 17.20. Planmed Oy
• 17.21. Samsung Medison Co Ltd
• 17.22. Shanghai United Imaging Healthcare Co Ltd
• 17.23. Shenzen Mindray Bio-Medical Electronics Co Ltd
• 17.24. Siemens Healthineers AG
• 17.25. Trivitron Healthcare
• 17.26. Villa Sistemi Medicali Spa